Status:
ACTIVE_NOT_RECRUITING
A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia
Lead Sponsor:
Bayer
Conditions:
Renal Anemia
Eligibility:
All Genders
20+ years
Brief Summary
In this study, the researchers want to learn more about the safety and effectiveness of Molidustat in Japanese men and women who have renal anemia, a condition in which the kidneys do not make enough ...
Eligibility Criteria
Inclusion
- Female or male participants with a diagnosis of renal anemia
- Decision to initiate treatment with Molidustat was made as per investigator's routine treatment practice
- Molidustat naïve participants (with including the participants treated within three months before the contracted date at each site)
- Signed informed consent
Exclusion
- \- Contra-indications according to the local marketing authorization
Key Trial Info
Start Date :
August 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2027
Estimated Enrollment :
1081 Patients enrolled
Trial Details
Trial ID
NCT04899661
Start Date
August 6 2021
End Date
September 30 2027
Last Update
December 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many facilities
Multiple Locations, Japan